Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AST 915 in patients with essential tremor.

Next Previous
Search
Trial Profile

AST 915 in patients with essential tremor.

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AST 915 (Primary)
  • Indications Essential tremor
  • Focus Adverse reactions

    • Most Recent Events

    • 16 Dec 2010 Results are expected to be presented at the 15th International Congress of Parkinson's Disease and Movement Disorders, according to a Manhattan Pharmaceuticals media release.
    • 16 Dec 2010 Primary endpoint 'Clinical-response' has not been met, according to a Manhattan Pharmaceuticals media release.
    • 16 Dec 2010 Interim results reported in a Manhattan Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top